{"id":"rt-cetuximab","safety":{"commonSideEffects":[{"rate":"70-80","effect":"Acneiform rash"},{"rate":"variable","effect":"Radiation dermatitis"},{"rate":"40-60","effect":"Mucositis"},{"rate":"variable","effect":"Dysphagia"},{"rate":"3-5","effect":"Infusion reactions"},{"rate":"13-17","effect":"Hypomagnesemia"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:35:57.615862","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetuximab binds to the epidermal growth factor receptor (EGFR) on cancer cells, blocking ligand-induced activation and downstream proliferation signaling. When combined with radiation therapy, EGFR inhibition enhances tumor cell radiosensitivity and reduces DNA repair capacity, leading to improved local control and cell death.","oneSentence":"RT+CETUXIMAB combines radiation therapy with cetuximab, an EGFR-blocking monoclonal antibody, to inhibit tumor cell growth and enhance radiosensitivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:40.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Head and neck cancer (squamous cell carcinoma)"},{"name":"Locally advanced cancers amenable to radiotherapy"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT04892173","phase":"PHASE3","title":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2021-12-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged","enrollment":500},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT07441681","phase":"PHASE3","title":"Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2027-01-06","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":454},{"nctId":"NCT03258554","phase":"PHASE2, PHASE3","title":"Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-03","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":196},{"nctId":"NCT07327411","phase":"PHASE2","title":"Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-27","conditions":"Advanced Refractory Solid Tumors","enrollment":40},{"nctId":"NCT00956007","phase":"PHASE3","title":"RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2010-03-31","conditions":"Head and Neck Cancer","enrollment":702},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT06706401","phase":"PHASE3","title":"Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-02-20","conditions":"Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer","enrollment":460},{"nctId":"NCT01326468","phase":"NA","title":"Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-12-08","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT03070366","phase":"PHASE2","title":"Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-09-21","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":78},{"nctId":"NCT00324415","phase":"PHASE2","title":"Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2006-09","conditions":"Anal Cancer","enrollment":45},{"nctId":"NCT05930938","phase":"PHASE3","title":"Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer","status":"TERMINATED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2023-12-12","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":19},{"nctId":"NCT02999087","phase":"PHASE3","title":"Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2017-09-14","conditions":"HNSCC","enrollment":707},{"nctId":"NCT03389477","phase":"PHASE2","title":"Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2018-04-27","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":26},{"nctId":"NCT04091867","phase":"PHASE1","title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":3},{"nctId":"NCT02573493","phase":"PHASE2","title":"Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04-13","conditions":"Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck","enrollment":96},{"nctId":"NCT01588431","phase":"PHASE2","title":"Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-12","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":3},{"nctId":"NCT00096174","phase":"PHASE2","title":"Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-04-08","conditions":"Head and Neck Cancer","enrollment":69},{"nctId":"NCT00089297","phase":"PHASE2","title":"Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-01-06","conditions":"Head and Neck Cancer","enrollment":74},{"nctId":"NCT01935921","phase":"PHASE1","title":"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-04-09","conditions":"Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7","enrollment":19},{"nctId":"NCT04106362","phase":"PHASE2","title":"Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-01-14","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant","enrollment":1},{"nctId":"NCT02707588","phase":"PHASE2","title":"Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2016-05-18","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":133},{"nctId":"NCT04359199","phase":"","title":"QUantitative Assessment of Swallowing After Radiation (QUASAR)","status":"UNKNOWN","sponsor":"Loren Mell, MD","startDate":"2020-09-01","conditions":"Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia","enrollment":42},{"nctId":"NCT01855451","phase":"PHASE3","title":"Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2013-06-03","conditions":"HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":189},{"nctId":"NCT00115700","phase":"PHASE3","title":"Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2000-02","conditions":"Follicular Lymphoma","enrollment":150},{"nctId":"NCT00533949","phase":"PHASE3","title":"High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2007-11","conditions":"Lung Cancer, Radiation Toxicity","enrollment":544},{"nctId":"NCT00265941","phase":"PHASE3","title":"Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2005-11","conditions":"Head and Neck Cancer","enrollment":940},{"nctId":"NCT00655876","phase":"PHASE3","title":"Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-06","conditions":"Esophageal Cancer","enrollment":344},{"nctId":"NCT00904345","phase":"PHASE2","title":"Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-04","conditions":"Head and Neck Cancer","enrollment":23},{"nctId":"NCT01107639","phase":"PHASE3","title":"Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-05-27","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer","enrollment":297},{"nctId":"NCT00721513","phase":"PHASE2","title":"Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-09","conditions":"Head and Neck Cancer","enrollment":20},{"nctId":"NCT02938273","phase":"PHASE1","title":"Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2017-02-01","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":10},{"nctId":"NCT01758731","phase":"PHASE1","title":"Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-10-22","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":17},{"nctId":"NCT00343083","phase":"PHASE2","title":"Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2004-12","conditions":"Cancer of Head and Neck","enrollment":43},{"nctId":"NCT00882583","phase":"PHASE1","title":"A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2009-07","conditions":"Head and Neck Cancer","enrollment":22},{"nctId":"NCT00084318","phase":"PHASE2","title":"Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2004-04","conditions":"Head and Neck Cancer","enrollment":238},{"nctId":"NCT01218048","phase":"PHASE2","title":"ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Robert Ferris","startDate":"2011-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":40},{"nctId":"NCT00686166","phase":"PHASE2","title":"S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-02","conditions":"Colorectal Cancer","enrollment":83},{"nctId":"NCT03051906","phase":"PHASE1, PHASE2","title":"Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2018-01","conditions":"Head and Neck Neoplasms","enrollment":69},{"nctId":"NCT00570674","phase":"PHASE1, PHASE2","title":"Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-11","conditions":"Squamous Cell Carcinoma of the Head and Neck, Basaloid Squamous Cell Carcinoma, Undifferentiated Carcinoma","enrollment":29},{"nctId":"NCT00999700","phase":"PHASE3","title":"Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2009-09","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":282},{"nctId":"NCT00704639","phase":"PHASE1, PHASE2","title":"Chemoradiation Treatment for Head and Neck Cancer","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2008-04","conditions":"Head and Neck Cancer","enrollment":60},{"nctId":"NCT01303237","phase":"","title":"A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-02-28","conditions":"Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck, LA SCCHN","enrollment":88},{"nctId":"NCT01794845","phase":"PHASE2","title":"Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2013-06-03","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer, Recurrent Disease","enrollment":5},{"nctId":"NCT01931150","phase":"PHASE3","title":"Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08","conditions":"Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT01050426","phase":"PHASE2","title":"A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)","status":"TERMINATED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2009-03","conditions":"Pancreatic Cancer","enrollment":17},{"nctId":"NCT00544362","phase":"PHASE1, PHASE2","title":"Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2007-07","conditions":"Esophageal Cancer","enrollment":33},{"nctId":"NCT02753140","phase":"PHASE2","title":"Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2016-04","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":60},{"nctId":"NCT00599131","phase":"PHASE2","title":"Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-08","conditions":"Cancer of Larynx","enrollment":4},{"nctId":"NCT00109850","phase":"PHASE2","title":"S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2005-05","conditions":"Esophageal Cancer","enrollment":22},{"nctId":"NCT01012258","phase":"PHASE3","title":"Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":70},{"nctId":"NCT01086826","phase":"PHASE3","title":"Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Associazione Volontari Pazienti Oncologici","startDate":"2008-03","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":320},{"nctId":"NCT00225784","phase":"PHASE2","title":"Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2005-02","conditions":"Pancreatic Cancer","enrollment":37},{"nctId":"NCT00865098","phase":"PHASE2","title":"Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-03","conditions":"Carcinoma of the Head and Neck","enrollment":27},{"nctId":"NCT01192087","phase":"PHASE1, PHASE2","title":"Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2012-06","conditions":"Adenoid Cystic Carcinoma","enrollment":49},{"nctId":"NCT00301028","phase":"PHASE2","title":"Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-04","conditions":"Head and Neck Cancer","enrollment":48},{"nctId":"NCT00288054","phase":"PHASE1","title":"S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2006-04","conditions":"Lung Cancer","enrollment":24},{"nctId":"NCT01760811","phase":"PHASE1, PHASE2","title":"CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2013-01","conditions":"Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT00115518","phase":"PHASE2","title":"Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2005-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT00251381","phase":"PHASE2","title":"Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.","status":"UNKNOWN","sponsor":"Trial Form Support S.L.","startDate":"2005-11","conditions":"Oropharyngeal Neoplasms","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Radiotherapy, Cetuximab"],"phase":"phase_3","status":"active","brandName":"RT+CETUXIMAB","genericName":"RT+CETUXIMAB","companyName":"Associazione Volontari Pazienti Oncologici","companyId":"associazione-volontari-pazienti-oncologici","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RT+CETUXIMAB combines radiation therapy with cetuximab, an EGFR-blocking monoclonal antibody, to inhibit tumor cell growth and enhance radiosensitivity. Used for Head and neck cancer (squamous cell carcinoma), Locally advanced cancers amenable to radiotherapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}